Medicare Targets Widely Used Drugs for Price Negotiation

The Biden administration has revealed the first batch of 10 prescription drugs that will be subject to price negotiations under a new federal law, including medications for conditions such as heart disease, diabetes, and autoimmune conditions. The selected drugs accounted for about 20% of total spending for Medicare Part D prescription drugs over the past year, costing Medicare and enrollees approximately $50.5 billion. While the negotiated prices won't take effect until 2026, other provisions promise more immediate savings, such as capping out-of-pocket expenses for prescriptions at $2,000 per year in 2025. The pharmaceutical industry has objected to the negotiations, filing lawsuits to halt the process.